Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 16, 2026

Motors and Drives Industry Research Report 2026: An $82.79 Billion Market by 2031 from $61 Billion in 2025 with ABB, Emerson Electric,. Nidec, Regal Rexnord, Rockwell Automation, and WEG Dominating

View original at globenewswire.com
Motors and Drives Industry Research Report 2026: An $82.79 Billion Market by 2031 from $61 Billion in 2025 with ABB, Emerson Electric,. Nidec, Regal Rexnord, Rockwell Automation, and WEG Dominating Dublin, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Motors and Drives Market was valued at USD 60.10 Billion in 2025, and is projected to reach USD 82.79 Billion by 2031, rising at a CAGR of 5.48%

    80% confidence

  • China alone installed more than 168,000 industrial robots in 2023, significantly boosting demand for high-efficiency motors and drives

    80% confidence

  • The market is shifting from traditional AC induction motor towards the sophisticated synchronous alternatives

    80% confidence

  • In some regions and countries, there is a goal for net-zero emission vehicle sales by 2035

    80% confidence

  • APAC is dominating the global motors & drives market, with a share of 45% in 2025

    80% confidence

  • The motors and drives market is a fragmented landscape primarily due to the presence of several global and regional companies and a diverse range of specialized product offerings

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com